Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Stanozolol in the Treatment of Pityriasis Rubra Pilaris

Stanozolol in the Treatment of Pityriasis Rubra Pilaris Abstract To the Editor.— In response to the short report by Pavlidakey et al1 in the Archives, we, too, were intrigued by the proposal of Finzi et al2 that the underlying defect in pityriasis rubra pilaris (PRP) might be a deficiency of retinol binding protein, resulting in inadequate transport of vitamin A to the skin. Their success in treating three patients with stanozolol,3 an anabolic steroid used to elevate the levels of retinol binding protein, was also of great interest. Our experience in using stanozolol in the treatment of PRP, however, has been less encouraging.In an attempt to duplicate the results of Finzi et al, we gathered a series of five patients with classic adult PRP, diagnosed on clinical grounds with supportive histopathology. As in the case reported by Pavlidakey et al, baseline retinol binding protein levels were within the normal range. Nevertheless, we proceeded with a References 1. Pavlidakey GP, Hashimoto K, Savoy LB, et al: Stanozolol in the treatment of pityriasis rubra pilaris . Arch Dermatol 1985;121:546-548.Crossref 2. Finzi AF, Altomare G, Bergamaschini L, et al: Pityriasis rubra pilaris and retinol-binding protein . Br J Dermatol 1981;104:253-256.Crossref 3. Bergamaschini L, Tucci A, Colombo A, et al: Effect of stanozolol in patients with pityriasis rubra pilaris and retinol-binding protein deficiency . N Engl J Med 1982;306:546-547. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Stanozolol in the Treatment of Pityriasis Rubra Pilaris

Archives of Dermatology , Volume 121 (9) – Sep 1, 1985

Loading next page...
 
/lp/american-medical-association/stanozolol-in-the-treatment-of-pityriasis-rubra-pilaris-1Q45Pygy0R

References (3)

Publisher
American Medical Association
Copyright
Copyright © 1985 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1985.01660090019004
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor.— In response to the short report by Pavlidakey et al1 in the Archives, we, too, were intrigued by the proposal of Finzi et al2 that the underlying defect in pityriasis rubra pilaris (PRP) might be a deficiency of retinol binding protein, resulting in inadequate transport of vitamin A to the skin. Their success in treating three patients with stanozolol,3 an anabolic steroid used to elevate the levels of retinol binding protein, was also of great interest. Our experience in using stanozolol in the treatment of PRP, however, has been less encouraging.In an attempt to duplicate the results of Finzi et al, we gathered a series of five patients with classic adult PRP, diagnosed on clinical grounds with supportive histopathology. As in the case reported by Pavlidakey et al, baseline retinol binding protein levels were within the normal range. Nevertheless, we proceeded with a References 1. Pavlidakey GP, Hashimoto K, Savoy LB, et al: Stanozolol in the treatment of pityriasis rubra pilaris . Arch Dermatol 1985;121:546-548.Crossref 2. Finzi AF, Altomare G, Bergamaschini L, et al: Pityriasis rubra pilaris and retinol-binding protein . Br J Dermatol 1981;104:253-256.Crossref 3. Bergamaschini L, Tucci A, Colombo A, et al: Effect of stanozolol in patients with pityriasis rubra pilaris and retinol-binding protein deficiency . N Engl J Med 1982;306:546-547.

Journal

Archives of DermatologyAmerican Medical Association

Published: Sep 1, 1985

There are no references for this article.